ABRF 2025
)
The Association of Biomolecular Resource Facilities (ABRF) Annual Meeting is an international program that provides timely updates on cutting-edge science and its execution in a shared resource/core facility setting. These meetings also offer informative and practical workshops as well as ample networking opportunities with academics, corporate, and technology partner colleagues.
Oxford Nanopore Technologies is sponsoring, exhibiting and presenting at ABRF 2025. Please register to join us on Monday, March 24, for a Breakfast Technology Showcase. Presentations and breakfast from 07:45 am—08:45 am PST.
You will also be able to find us at booth 109 throughout the conference. We hope to see you there!
Breakfast Technology Showcase
Date: Monday, March 24, 2025
Time: 07:45 am—08:45 am PST
Location: Skyview 1
Join us at the ABRF workshop to discover how Oxford Nanopore Technologies' sequencing platform is driving advancements in multiomics research.
Dr. Winston Timp's presentation will elaborate on how integration of Oxford Nanopore sequencing with single-cell and spatial transcriptomic methods is uncovering new insights into brain function and cancer biology. See how full-length transcript sequencing reveals isoform changes in the mouse hippocampus, maps layer-specific expression in the human brain, and identifies alternative splicing events and mutations in pancreatic cancer organoids.
Additionally, don’t miss Dr. Brandon Blakey's talk that will highlight how complete genetic information—including structural variants, haplotypes, and methylation—is essential for advancing our understanding of human diseases. In this session explore how Oxford Nanopore’s sequencing technology is expanding the boundaries of sequencing and enabling deeper understanding of disease mechanisms.
This breakfast is open to ABRF meeting attendees. Space is limited so register early to secure your spot.
Breakfast Technology Showcase
07:45 am—08:45 am PST | Breakfast Technology Showcase | |
|---|---|---|
07:45 am—07:55 am | Oxford Nanopore Updates | Gus Potamousis, Oxford Nanopore Technologies |
07:55 am—08:20 am | Decoding complex biological systems with single-cell and spatial long-read transcriptomics | Winston Timp, Johns Hopkins University |
08:20 am—08:45 am | Calling variants in human samples using automated EPI2ME end-to-end workflows | Brandon Blakey, Oxford Nanopore Technologies |
Speakers
)
Gus Potamousis, Director of Strategic Accounts, Oxford Nanopore TechnologiesOver the past five years, long-read sequencing has matured rapidly, improving in accuracy, throughput, and accessibility. But to understand what's happening in tissue, with its complex mixtures of different cell types, we need to combine long reads with single-cell and spatial methods. Here we demonstrate the application of nanopore sequencing paried to 10X methods in brain and cancer samples to explore the transcriptome. First, we paired nanopore sequencing with 10X Chromium to explore transcript isoforms in the mouse hippocampus to understand isoform changes during learning. With single-cell long read sequencing, we interrogated cell type-specific alternative splicing events and isoform switching mechanisms that correlate with memory formation. Such isoform-level information proves especially important in brain tissue, where splicing changes inform function. Secondly, we integrated nanopore long-read sequencing with spatial barcoding (Visium) to map isoform expression across distinct layers of the human dorsolateral prefrontal cortex (DLPFC). This approach enabled identification of layer-specific isoform signatures that may contribute to functional specialization. Finally, we applied single-cell long-read sequencing to pancreatic cancer organoids, enabling simultaneous detection of alternative splicing events and somatic mutations within individual cells. By getting the entire transcript, we can look at mutations which are transcribed in each individual cell. We believe this will eventually lead us to be able to reconstruct a full phylogenetic tree of a cancer sample, understanding the clonality of the mutations and the timeline over which they are acquired, as well as their importance to cancer development. This demonstrates how nanopore-based transcriptomics can advance precision oncology through comprehensive characterization of transcript diversity in heterogeneous tumor populations.
Over the past five years, long-read sequencing has matured rapidly, improving in accuracy, throughput, and accessibility. But to understand what's happening in tissue, with its complex mixtures of different cell types, we need to combine long reads with single-cell and spatial methods. Here we demonstrate the application of nanopore sequencing paried to 10X methods in brain and cancer samples to explore the transcriptome. First, we paired nanopore sequencing with 10X Chromium to explore transcript isoforms in the mouse hippocampus to understand isoform changes during learning. With single-cell long read sequencing, we interrogated cell type-specific alternative splicing events and isoform switching mechanisms that correlate with memory formation. Such isoform-level information proves especially important in brain tissue, where splicing changes inform function. Secondly, we integrated nanopore long-read sequencing with spatial barcoding (Visium) to map isoform expression across distinct layers of the human dorsolateral prefrontal cortex (DLPFC). This approach enabled identification of layer-specific isoform signatures that may contribute to functional specialization. Finally, we applied single-cell long-read sequencing to pancreatic cancer organoids, enabling simultaneous detection of alternative splicing events and somatic mutations within individual cells. By getting the entire transcript, we can look at mutations which are transcribed in each individual cell. We believe this will eventually lead us to be able to reconstruct a full phylogenetic tree of a cancer sample, understanding the clonality of the mutations and the timeline over which they are acquired, as well as their importance to cancer development. This demonstrates how nanopore-based transcriptomics can advance precision oncology through comprehensive characterization of transcript diversity in heterogeneous tumor populations.
)
Dr. Winston Timp, Johns Hopkins University)
Brandon Blakey, Oxford Nanopore Technologies
